Bruker Competitors

Thermo Fisher Scientific (NYSE:TMO) and Bruker (NASDAQ:BRKR) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, risk, institutional ownership, profitability and valuation.

Risk and Volatility

Thermo Fisher Scientific has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500. Comparatively, Bruker has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500.

Institutional and Insider Ownership

87.2% of Thermo Fisher Scientific shares are held by institutional investors. Comparatively, 65.9% of Bruker shares are held by institutional investors. 0.4% of Thermo Fisher Scientific shares are held by company insiders. Comparatively, 26.8% of Bruker shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Thermo Fisher Scientific and Bruker's net margins, return on equity and return on assets.

Dividends

Thermo Fisher Scientific pays an annual dividend of $1.04 per share and has a dividend yield of 0.2%. Bruker pays an annual dividend of $0.16 per share and has a dividend yield of 0.2%. Thermo Fisher Scientific pays out 8.4% of its earnings in the form of a dividend. Bruker pays out 10.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Thermo Fisher Scientific has increased its dividend for 3 consecutive years and Bruker has increased its dividend for 1 consecutive years.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Thermo Fisher Scientific and Bruker, as reported by MarketBeat.com.

Thermo Fisher Scientific presently has a consensus target price of $536.8947, indicating a potential upside of 18.06%. Bruker has a consensus target price of $62.00, indicating a potential downside of 6.70%. Given Thermo Fisher Scientific's stronger consensus rating and higher possible upside, analysts plainly believe Thermo Fisher Scientific is more favorable than Bruker.

Valuation & Earnings

This table compares Thermo Fisher Scientific and Bruker's gross revenue, earnings per share (EPS) and valuation.

Thermo Fisher Scientific has higher revenue and earnings than Bruker. Thermo Fisher Scientific is trading at a lower price-to-earnings ratio than Bruker, indicating that it is currently the more affordable of the two stocks.

Summary

Thermo Fisher Scientific beats Bruker on 12 of the 17 factors compared between the two stocks.

Bruker (NASDAQ:BRKR) and Illumina (NASDAQ:ILMN) are both large-cap computer and technology companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, profitability, institutional ownership, dividends and valuation.

Risk & Volatility

Bruker has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Comparatively, Illumina has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500.

Institutional and Insider Ownership

65.9% of Bruker shares are owned by institutional investors. Comparatively, 90.0% of Illumina shares are owned by institutional investors. 26.8% of Bruker shares are owned by company insiders. Comparatively, 0.4% of Illumina shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Bruker and Illumina's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings and recommmendations for Bruker and Illumina, as reported by MarketBeat.

Bruker presently has a consensus price target of $62.00, indicating a potential downside of 6.70%. Illumina has a consensus price target of $374.50, indicating a potential upside of 0.45%. Given Illumina's higher possible upside, analysts plainly believe Illumina is more favorable than Bruker.

Earnings & Valuation

This table compares Bruker and Illumina's top-line revenue, earnings per share and valuation.

Illumina has higher revenue and earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Summary

Illumina beats Bruker on 10 of the 14 factors compared between the two stocks.

Bruker (NASDAQ:BRKR) and Agilent Technologies (NYSE:A) are both large-cap computer and technology companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, profitability, institutional ownership, dividends and valuation.

Profitability

This table compares Bruker and Agilent Technologies' net margins, return on equity and return on assets.

Risk & Volatility

Bruker has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500. Comparatively, Agilent Technologies has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Bruker and Agilent Technologies, as reported by MarketBeat.

Bruker presently has a consensus price target of $62.00, indicating a potential downside of 6.70%. Agilent Technologies has a consensus price target of $107.4350, indicating a potential downside of 16.48%. Given Bruker's higher possible upside, equities analysts plainly believe Bruker is more favorable than Agilent Technologies.

Earnings & Valuation

This table compares Bruker and Agilent Technologies' revenue, earnings per share (EPS) and valuation.

Agilent Technologies has higher revenue and earnings than Bruker. Agilent Technologies is trading at a lower price-to-earnings ratio than Bruker, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

65.9% of Bruker shares are owned by institutional investors. 26.8% of Bruker shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Dividends

Bruker pays an annual dividend of $0.16 per share and has a dividend yield of 0.2%. Agilent Technologies pays an annual dividend of $0.78 per share and has a dividend yield of 0.6%. Bruker pays out 10.2% of its earnings in the form of a dividend. Agilent Technologies pays out 23.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bruker has raised its dividend for 1 consecutive years and Agilent Technologies has raised its dividend for 1 consecutive years.

Summary

Agilent Technologies beats Bruker on 9 of the 16 factors compared between the two stocks.

Mettler-Toledo International (NYSE:MTD) and Bruker (NASDAQ:BRKR) are both large-cap computer and technology companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, valuation, earnings and profitability.

Institutional and Insider Ownership

93.2% of Mettler-Toledo International shares are held by institutional investors. Comparatively, 65.9% of Bruker shares are held by institutional investors. 3.2% of Mettler-Toledo International shares are held by insiders. Comparatively, 26.8% of Bruker shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Mettler-Toledo International and Bruker's top-line revenue, earnings per share (EPS) and valuation.

Mettler-Toledo International has higher revenue and earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Mettler-Toledo International has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500. Comparatively, Bruker has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Mettler-Toledo International and Bruker, as provided by MarketBeat.com.

Mettler-Toledo International presently has a consensus price target of $1,048.3333, indicating a potential downside of 15.56%. Bruker has a consensus price target of $62.00, indicating a potential downside of 6.70%. Given Bruker's stronger consensus rating and higher possible upside, analysts clearly believe Bruker is more favorable than Mettler-Toledo International.

Profitability

This table compares Mettler-Toledo International and Bruker's net margins, return on equity and return on assets.

Summary

Mettler-Toledo International beats Bruker on 8 of the 14 factors compared between the two stocks.

Bruker (NASDAQ:BRKR) and Waters (NYSE:WAT) are both large-cap computer and technology companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings and valuation.

Insider and Institutional Ownership

65.9% of Bruker shares are held by institutional investors. Comparatively, 91.8% of Waters shares are held by institutional investors. 26.8% of Bruker shares are held by company insiders. Comparatively, 1.5% of Waters shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Bruker and Waters' top-line revenue, earnings per share (EPS) and valuation.

Waters has higher revenue and earnings than Bruker. Waters is trading at a lower price-to-earnings ratio than Bruker, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Bruker has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, Waters has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Bruker and Waters, as provided by MarketBeat.

Bruker presently has a consensus price target of $62.00, suggesting a potential downside of 6.70%. Waters has a consensus price target of $251.25, suggesting a potential downside of 17.25%. Given Bruker's stronger consensus rating and higher possible upside, equities analysts plainly believe Bruker is more favorable than Waters.

Profitability

This table compares Bruker and Waters' net margins, return on equity and return on assets.

Bruker (NASDAQ:BRKR) and Bio-Rad Laboratories (NYSE:BIO) are both large-cap computer and technology companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings and valuation.

Insider and Institutional Ownership

65.9% of Bruker shares are held by institutional investors. Comparatively, 63.0% of Bio-Rad Laboratories shares are held by institutional investors. 26.8% of Bruker shares are held by company insiders. Comparatively, 27.5% of Bio-Rad Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Bruker and Bio-Rad Laboratories' top-line revenue, earnings per share (EPS) and valuation.

Bio-Rad Laboratories has higher revenue and earnings than Bruker. Bruker is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Bruker has a beta of 1.29, suggesting that its share price is 29% more volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Bruker and Bio-Rad Laboratories, as provided by MarketBeat.

Bruker presently has a consensus price target of $62.00, suggesting a potential downside of 6.70%. Bio-Rad Laboratories has a consensus price target of $700.00, suggesting a potential upside of 19.89%. Given Bio-Rad Laboratories' stronger consensus rating and higher possible upside, analysts plainly believe Bio-Rad Laboratories is more favorable than Bruker.

Profitability

This table compares Bruker and Bio-Rad Laboratories' net margins, return on equity and return on assets.

Summary

Bio-Rad Laboratories beats Bruker on 8 of the 13 factors compared between the two stocks.